William Whalen - Concepedia

Author

William Whalen

Also Known As

Floreliz Mendoza, Jamie Saunders, Jamuna Kirshnan, Jamuna Krishnan, Laura Novik, W A Whalen, W Whalen, Whalen, William, Alexander, William A Whalen, William A. Whalen

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health Brigham and Women's Hospital Cornell University Weill Cornell Medicine UConn Health

About

William Whalen is an author at National Institutes of Health specializing in medicine, molecular biology, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.1K
2	Natural Sciences	8	8	405
3	Biochemistry	4	4	96
4	Biology	2	2	39
5	Public Health	1	1	37

William Whalen

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States Jennifer E. Flythe, Magdalene M. Assimon, Matthew J. Tugman, American Journal of Kidney Diseases HemodialysisIntensive Care UnitsMedicineKidney FailureAcute Care	2020	231
A Mutation in the Schizosaccharomyces pombe rae1 Gene Causes Defects in Poly(A)+ RNA Export and in the Cytoskeleton Julie A. Brown, Anekella Bharathi, Anil K. Ghosh, Journal of Biological Chemistry	1995	152
An antitermination protein engages the elongating transcription apparatus at a promoter-proximal recognition site Sailen Barik, Balaram Ghosh, William Whalen, Cell ChromatinTranscriptional RegulationProtein ExpressionAntitermination ProteinNatural Sciences	1987	128
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial Martin R. Gaudinski, Katherine V. Houser, Nicole A. Doria‐Rose, The Lancet HIV ImmunologyPharmacologyTherapeutic EfficacyAntibody ScreeningAntibody Engineering	2019	105
NusA protein is necessary and sufficient in vitro for phage lambda N gene product to suppress a rho-independent terminator placed downstream of nutL. William Whalen, Balaram Ghosh, Anindya Das Proceedings of the National Academy of Sciences Transcription AntiterminationGeneticsMolecular BiologyMolecular GeneticsGene Transcription	1988	72
Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial Tracy J. Ruckwardt, Kaitlyn M. Morabito, Emily Phung, The Lancet Respiratory Medicine VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirology	2021	62
The human RAE1 gene is a functional homologue of Schizosaccharomyces pombe rae1 gene involved in nuclear export of Poly(A)+ RNA Anekella Bharathi, Anil K. Ghosh, William Whalen, Gene Nuclear ExportFunctional HomologueNatural SciencesGeneticsRna Biology	1997	61
Hospital-Level Variation in Death for Critically Ill Patients with COVID-19 Matthew M. Churpek, Shruti Gupta, Alexandra B. Spicer, American Journal of Respiratory and Critical Care Medicine	2021	55

Page 1